NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed a research agreement with Spain's Instituto Valenciano de Oncología (IVO) to develop and validate a breast cancer recurrence risk score using the company's technology.

Under the terms of the deal, the partners will use HTG's EdgeSeq Oncology biomarker panel to develop a breast cancer recurrence risk score based on genes differentially expressed in patients with low and high risk of recurrence. Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.